循環器ジャーナル71巻4号

2023年10月発行

特集 変革期を迎えた肺高血圧症—次世代の病態理解，診断，治療とは？

Ⅲ.肺高血圧症における最新トピックス

肺高血圧症における新規治療法開発の現状と将来展望

著者： 佐藤大樹¹ 矢尾板信裕¹ 安田聡¹

所属機関： ¹東北大学病院循環器内科

ページ範囲：P.597 - P.601

文献概要

POINT
●肺動脈性肺高血圧症の病因は肺動脈リモデリングであり，基礎研究が積み重ねなられてきた．
●実臨床で応用可能な肺動脈リモデリングの評価・治療方法は未確立である．
●基礎研究と実臨床をつなぐブレイクスルーとなる技術革新，評価・治療戦略が期待される．

参考文献

1）Tokunaga N, Ogawa A, Matsubara H, et al. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J Cardiol 2016 ; 68 : 542-7.

2）Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014 ; 115 : 165-75.

3）Morrell NW. Pulmonary hypertension due to BMPR2 mutation : a new paradigm for tissue remodeling? Proc Am Thorac Soc 2006 ; 3 : 680-6.

4）Hoeper MM, Badesch DB, Ghofrani HA, et al ; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2023 ; 388 : 1478-90.

5）Ko T, Nomura S, Yamada S, et al. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF-β-IGFBP7 axis. Nat Commun 2022 ; 13 : 3275.

6）Wu Y, Wharton J, Walters R, et al. The pathophysiological role of novel pulmonary arterial hypertension gene SOX17. Eur Respir J 2021 ; 58 : 2004172.

7）Abe K, Toba M, Alzoubi A, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010 ; 121 : 2747-54.

8）Sugimura K, Fukumoto Y, Miura Y, et al. Three-dimensional-optical coherence tomography imaging of chronic thromboembolic pulmonary hypertension. Eur Heart J 2013 ; 34 : 2121.

9）Satoh T, Wang L, Espinosa-Diez C, et al. Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Circulation 2021 ; 144 : 615-37.

10）Yu Q, Tai YY, Tang Y, et al. BOLA（BolA Family Member 3）Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. Circulation 2019 ; 139 : 2238-55.

11）Nakamura K, Akagi S, Ejiri K, et al. Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension. Int J Mol Sci 2019 ; 20 : 5885.

12）Kuwana M, Abe K, Kinoshita H, et al. Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension. Pulm Circ 2023 ; 13 : e12198.